Glycomimetics Stock News

Wall Street analysts forecast that GlycoMimetics, Inc. (NASDAQ:GLYC) will announce earnings of ($0.31) per share for the current quarter, according to Zacks. Zero analysts have made estimates for GlycoMimetics earnings, with the highest EPS estimate coming in at ($0.27) and the lowest estimate coming in at ($0.36). GlycoMimetics posted earnings of ($0.32) per share during []

Equities analysts expect GlycoMimetics, Inc. (NASDAQ:GLYC) to report ($0.31) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for GlycoMimetics earnings. The highest EPS estimate is ($0.27) and the lowest is ($0.36). GlycoMimetics reported earnings per share of ($0.32) during the same quarter last year, which indicates a []

Squarepoint Ops LLC purchased a new stake in GlycoMimetics, Inc. (NASDAQ:GLYC) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 16,216 shares of the biotechnology companys stock, valued at approximately $38,000. Several other large investors have also recently made changes to []

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (the Company) (NASDAQ:GLYC) today announced that the compensation committee of the Companys Board of Directors approved the grant on November 22, 2021 of a non-qualified stock option award to purchase an aggregate of 100,000 shares to one new employee. The award was granted as an inducement equity award outside of the Companys 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4), and was made as an inducement mater

AQR Capital Management LLC cut its stake in GlycoMimetics, Inc. (NASDAQ:GLYC) by 54.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 97,590 shares of the biotechnology companys stock after selling 114,498 shares during the quarter. AQR Capital Management LLC owned 0.19% []

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Apollomics has dosed the first patient in China in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). Apollomics’ Phase 3 trial with APL-106 is part of the overall development program for Apollomics in China that also includes an ongoing Phase 1 pharmacokinetics (PK) and tolerability study. The Phase 3 clinical tr

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Lisa DeLuca, Ph.D., has joined its executive leadership team as Vice President, Regulatory Affairs. Dr. DeLuca is a veteran regulatory expert who has previously led the strategy-formation and execution of multiple global NDA submissions and product registrations. Most recently she was the head of regulatory affairs at Nuvation Bio and a member of its executive leadership team. Lisa is a seasoned executive

GlycoMimetics, Inc. (NASDAQ:GLYC) Director Patricia S. Andrews bought 40,000 shares of the businesss stock in a transaction on Tuesday, November 16th. The stock was acquired at an average cost of $2.05 per share, for a total transaction of $82,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this []

Zacks Investment Research upgraded shares of GlycoMimetics (NASDAQ:GLYC) from a sell rating to a hold rating in a research note released on Wednesday morning, Zacks.com reports. According to Zacks, GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays []

Jefferies Financial Group upgraded shares of GlycoMimetics (NASDAQ:GLYC) from a hold rating to a buy rating in a research report sent to investors on Friday, Analyst Price Targets reports. The brokerage currently has $4.00 price target on the biotechnology companys stock, up from their previous price target of $3.00. GLYC has been the topic of []

GlycoMimetics (NASDAQ:GLYC) was upgraded by equities researchers at Jefferies Financial Group from a hold rating to a buy rating in a note issued to investors on Friday, Analyst Price Targets reports. The firm currently has a $4.00 price target on the biotechnology companys stock, up from their prior price target of $3.00. Jefferies Financial Groups []

GlycoMimetics' main AML trial is close to completion of enrollment. Uproleselan Phase 3 trial likely to build on prior positive data.

Are these on your list of penny stocks to watch today? The post Hot Penny Stocks To Buy Now?

GlycoMimetics, Inc. (GLYC) CEO Harout Semerjian on Q3 2021 Results - Earnings Call Transcript

GlycoMimetics Inc (NASDAQ: GLYC) has announced that efficacy and safety data from a Phase 1/2 study of uproleselan were published online in the journal BLOOD.  In the manuscript, scientists highlig